Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for IMR-90 Cells (Lung Fibroblast Cells, CCL-186)
- Two component formulation enhances lipid mediated transfection efficiency
- Kit includes Transfection Enhancer reagent and recommended transfection protocol
- Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
- Reproducible transfection results
- Works well for standard reverse transfection and high-throughput applications
- Download IMR-90 CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for IMR-90 cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems IMR90 Transfection Protocol: [PDF]
Download MSDS: [PDF]
IMR-90 Cell Line:
Fibroblasts are the most common connective tissue cells present in the body that are responsible for making up the structural framework since they produce the extracellular matrix and collagen. Fibroblasts are elongated cells with a round or oval nucleus that can be seen in the interstitial spaces of organs. Active fibroblasts are usually larger and contain abundant rough endoplasmic reticulum. In the lung, they are typically situated in highly complex multicellular environments. A better understanding of different fibroblast phenotypes could accelerate the path to discovery of targeted therapeutics.
The IMR-90 cell line was established in 1975 from lung fibroblasts of a 16-week-old Caucasian female fetus by W. W. Nichols and associates and is a suitable transfection host for a variety of research related to molecular biology. The IMR-90 cell line displays characteristics of both fibroblasts and differentiated smooth muscle cells and can reach roughly 58 population doublings before the onset of senescence (aging). These cells are highly utilized as model fibroblasts in a broad array of studies. At the same time, they exhibit various characteristics of differentiated smooth muscle cells, including the same elongated form as well as the longitudinal alignment of their actin-attachment sites. Altogen Biosystems provides two-components highly efficient transfection reagent kits for this cell line.
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the IMR-90 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=6).
Figure 2. Protein expression of Cyclophilin B in IMR-90 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into IMR-90 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life science research. Transfection products are developed for individual cancer cell line and transfection protocols are optimized to enable high transfection efficiency of biomolecules. Altogen Biosystems developed in vivo delivery products for small animal research, mouse and rat targeted tissue delivery: liver targeted, pancreas targeted, kidney targeted, PEG-Liposome-, Nanoparticle-, Lipid-, and Polymer-based in vivo transfection kits. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of biomolecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6830)
- 1.5 ml (Catalog #6831)
- 1.5 ml CRISPR (Catalog #2160)
- 8.0 ml (Catalog #6832)